{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T17:50:31Z","timestamp":1773683431112,"version":"3.50.1"},"reference-count":33,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2012,3,29]],"date-time":"2012-03-29T00:00:00Z","timestamp":1332979200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cytometry Part B Clinical"],"published-print":{"date-parts":[[2012,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background:<\/jats:title><jats:p>In addition to standard risk criteria at diagnosis, minimal residual disease (MRD) following initiation of therapy is a well\u2010recognized risk factor to predict relapse. Literature from developing countries addressing therapeutic or laboratory practices related to MRD, is largely lacking. In a first paper from India, we describe our experience in establishing a flow cytometry\u2010based MRD assay for precursor B lineage ALL (BCP\u2010ALL) with emphasis on the assay standardization and cost.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>Normal templates for B cell development were established in 10 control patients using CD45, CD11a, CD38, CD20, CD10, CD19, CD58, CD34, CD123, and CD22. BCP\u2010ALL samples (<jats:italic>n<\/jats:italic> = 42) were characterized at diagnosis to identify a suitable marker for follow\u2010up during mid (D+21) and end of induction (D+33). Both, multiparametric immunophenotyping and single marker detection of LAIP were used for data analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>In 95.2% of BCP\u2010ALL at least two informative markers could be obtained when a minimum of four cocktail combinations were used. The combination CD20, CD10, CD45, and CD19 was the most useful (71.4%) followed by combinations containing CD38 (66.7%), CD22 (57.1%), CD11a (52.4%), and CD58 (33.3%). Using our approach, 60 and 47% of patients had detectable MRD at mid and end induction time points, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>We have described a relatively cost effective MRD panel which is applicable to over 90% of patients. We hope that this data would encourage more centers in India and other resource constrained health delivery systems to develop MRD assays. \u00a9 2012 International Clinical Cytometry Society<\/jats:p><\/jats:sec>","DOI":"10.1002\/cyto.b.21017","type":"journal-article","created":{"date-parts":[[2012,4,2]],"date-time":"2012-04-02T13:34:57Z","timestamp":1333373697000},"page":"252-258","source":"Crossref","is-referenced-by-count":32,"title":["Standardizing minimal residual disease by flow cytometry for precursor B lineage acute lymphoblastic leukemia in a developing country"],"prefix":"10.1002","volume":"82B","author":[{"given":"Nikhil","family":"Patkar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ansu Abu","family":"Alex","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bargavi","family":"B.","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rayaz","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aby","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biju","family":"George","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Auro","family":"Vishwabandya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alok","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikram","family":"Mathews","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,3,29]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra023001"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra052603"},{"key":"e_1_2_5_4_2","volume-title":"Hematology: Basic Principles and Practice","author":"Ronald Hoffman BF","year":"2009"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)10295-1"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200004063421402"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)04058-6"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-132837"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-10-248146"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.268"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0900386"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02560.x"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402150"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22261"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0320(19990815)38:4<139::AID-CYTO1>3.0.CO;2-H"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.6.1952"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2008.000414"},{"key":"e_1_2_5_18_2","unstructured":"Curr Protoc Cytom 2001 Common stock solutions buffers and media"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0320(19971015)30:5<236::AID-CYTO4>3.0.CO;2-F"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401364"},{"key":"e_1_2_5_21_2","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1182\/blood.V72.1.299.299","article-title":"Asynchronous antigen expression in B lineage acute lymphoblastic leukemia","volume":"72","author":"Hurwitz CA","year":"1988","journal-title":"Blood"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.136"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-472X(98)00071-X"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-01-0006"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.8934"},{"key":"e_1_2_5_26_2","first-page":"675","article-title":"New methodologic approaches for immunophenotyping acute leukemias","volume":"86","author":"Basso G","year":"2001","journal-title":"Haematologica"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1521-6926(03)00067-7"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402736"},{"key":"e_1_2_5_29_2","first-page":"1109","article-title":"Methodological approach to minimal residual disease detection by flow cytometry in adult B\u2010lineage acute lymphoblastic leukemia","volume":"91","author":"Krampera M","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1159\/000077554"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.20430"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2008.000299"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-324004"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.a.20638"}],"container-title":["Cytometry Part B: Clinical Cytometry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcyto.b.21017","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cyto.b.21017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T14:14:40Z","timestamp":1700576080000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cyto.b.21017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,29]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["10.1002\/cyto.b.21017"],"URL":"https:\/\/doi.org\/10.1002\/cyto.b.21017","archive":["Portico"],"relation":{},"ISSN":["1552-4949","1552-4957"],"issn-type":[{"value":"1552-4949","type":"print"},{"value":"1552-4957","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,29]]}}}